公开(公告)号：US20240335548A1

公开(公告)日：2024-10-10

申请号：US18507435

申请日：2023-11-13

Applicant: Starpharma Pty Ltd

Inventor： David Owen ,  Brian Devlin Kelly ,  Peter Karellas

IPC: A61K47/59 ,  A61K47/60 ,  A61K47/64 ,  A61K47/65 ,  A61K47/68 ,  C08G69/10 ,  C08G69/40 ,  C08G69/48 ,  C08G83/00

CPC classification number: A61K47/59 ,  A61K47/60 ,  A61K47/645 ,  A61K47/65 ,  A61K47/68 ,  A61K47/6885 ,  C08G69/10 ,  C08G69/40 ,  C08G69/48 ,  C08G83/003 ,  C08G83/004

Abstract: A macromolecule includes i) a dendrimer comprising a core and at least one generation of building units, the outermost generation of building units having surface amino groups wherein at least two different terminal groups are covalently attached to the surface amino groups of the dendrimer, ii) a first terminal group which is a residue of a pharmaceutically active agent comprising a hydroxyl group, and iii) a second terminal group which is a pharmacokinetic modifying agent. The pharmaceutically active agent is cabazitaxel. The first terminal group is covalently attached to the surface amino group of the dendrimer through a diacid linker, the diacid linker comprising an alkyl chain interrupted by one or more oxygen, sulfur or nitrogen atoms, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240316208A1

公开(公告)日：2024-09-26

申请号：US18654735

申请日：2024-05-03

Applicant: Serina Therapeutics (AL), Inc.

Inventor： J Milton HARRIS ,  Michael D. BENTLEY ,  Tacey X. VIEGAS ,  Randall W. MOREADITH ,  Zhihao FANG ,  Kunsang YOON ,  Rebecca WEIMER

IPC: A61K47/59 ,  A61K31/05

CPC classification number: A61K47/59 ,  A61K31/05

Abstract: Polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer and methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions including a POZ conjugate are also provided.

公开(公告)号：US20240293316A1

公开(公告)日：2024-09-05

申请号：US18415811

申请日：2024-01-18

Applicant: Ramot at Tel-Aviv University Ltd. ,  Northwestern University

Inventor： Nathan GIANNESCHI ,  Yifei LIANG ,  Claudia Battistella ,  Lihi ADLER-ABRAMOVICH ,  Eyal ROSEN ,  Carlos NEMCOVSKY ,  Nathan SCHIFFMANN ,  Michal HALPERIN-STERNFELD

IPC: A61K9/107 ,  A61K47/59

CPC classification number: A61K9/1075 ,  A61K47/59

Abstract: Micellar particles formed of a plurality of block copolymers, compositions comprising same, copolymers used to form the particles, and polymeric aggregates formed therefrom are provided. The micellar particles are for use in the treatment of inflammation, including chronic inflammation. The block copolymers forming the particles include at least a first block and a second block. The first block has an anti-inflammatory agent covalently attached, directly or via a linking moiety or group, to at least a portion of its backbone units; and the second block has a hydrophilic moiety that comprises an amino acid sequence that is capable of interacting with an inflammatory biomarker covalently attached to at least a portion of its backbone units, and the particle features a core made of the first block and a hydrophilic shell made of the second block.

公开(公告)号：US20240209361A1

公开(公告)日：2024-06-27

申请号：US18288457

申请日：2022-04-27

Applicant: The Johns Hopkins University ,  Regents of the University of Minnesota

Inventor： Efrosini Kokkoli ,  Clark C. Chen ,  Zachary Schneiderman

IPC: C12N15/113 ,  A61K9/127 ,  A61K9/51 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  A61N5/10 ,  A61P35/00

CPC classification number: C12N15/113 ,  A61K9/1272 ,  A61K9/5169 ,  A61K47/59 ,  A61K47/64 ,  A61K47/6911 ,  A61N5/10 ,  A61P35/00 ,  C12N15/1135 ,  A61N2005/1098 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2320/31

Abstract: This document relates to methods and materials for treating cancer. For example, this document provides nanoparticles (e.g., liposomes and LNPs) encapsulating one or more microRNAs and/or one or more anti-microRNAs. In some cases, nanoparticles (e.g., liposomes and LNPs) encapsulating one or more microRNAs and/or one or more anti-microRNAs can be administered to a mammal (e.g., a human) having cancer to treat the mammal.

公开(公告)号：US20240180849A1

公开(公告)日：2024-06-06

申请号：US18285439

申请日：2022-04-12

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Jianping Wang ,  Fanfei Meng

IPC: A61K9/70 ,  A61K45/06 ,  A61K47/59 ,  A61K49/00 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K9/70 ,  A61K45/06 ,  A61K47/59 ,  A61K49/0054 ,  A61P35/00 ,  C12N15/1138 ,  A61K2123/00 ,  C12N2310/141

Abstract: The present disclosure generally relates to a composition matter and a method for cancer treatment. In particular, a composition matter as an antitumor immunotherapy comprising a polyethyleneimine derivative as an immunoadjuvant, a chemotherapeutic drug, and optional components such as a microRNA, messenger RNA, plasmid DNA, siRNA, oligonucleotide, or a cyclic dinucleotide. A method for treating a subject with a cancer by administrating a therapeutic effective amount of a composition comprising a polyethyleneimine derivative and an antitumor agent to the subject in need of relief from said cancer is also within the scope of this disclosure.

公开(公告)号：US11986533B2

公开(公告)日：2024-05-21

申请号：US17648642

申请日：2022-01-21

Applicant: Regents of the University of Minnesota

Inventor： Theresa Reineke ,  Frank S. Bates ,  Monica Ohnsorg

IPC: A61K47/59 ,  C08G81/02

CPC classification number: A61K47/59 ,  C08G81/024

Abstract: A composition includes a macromolecular polyacrylamide copolymer excipient with an α-end including a ROMP-active norbornene end-group and a ω-end including a terminal monomer with an end group chosen from: a hydrogen atom (H); or a functionalized acrylate with functionality chosen from alkyl, hydroxyl (OH), methyl-polyethylene glycol ((PEG)-CH3), hydroxy-PEG (PEG-OH), carboxylic acid (COOH), and combinations thereof. A biological compound chosen from active pharmaceutical ingredients, proteins, polynucleotides, and mixtures and combinations thereof is non-covalently bound with the macromolecular excipient.

公开(公告)号：US11925689B2

公开(公告)日：2024-03-12

申请号：US17568042

申请日：2022-01-04

Applicant: Serina Therapeutics, Inc.

Inventor： J Milton Harris ,  Kunsang Yoon ,  Michael David Bentley ,  Zhihao Fang ,  Tacey Viegas

IPC: C08G73/02 ,  A61K38/09 ,  A61K47/59 ,  A61P35/00

CPC classification number: A61K47/59 ,  A61K38/09 ,  A61P35/00 ,  C08G73/0233

Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.

公开(公告)号：US11890347B2

公开(公告)日：2024-02-06

申请号：US16468199

申请日：2017-12-05

Applicant: Tokyo Institute of Technology

Inventor： Nobuhiro Nishiyama ,  Hiroyasu Takemoto ,  Abdul-Hackam Ranneh ,  Keishiro Tomoda ,  Takahiro Nomoto ,  Makoto Matsui

IPC: A61K47/59 ,  C08G69/48

CPC classification number: A61K47/59 ,  C08G69/48

Abstract: A pH-responsive polymer formed of a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded.

公开(公告)号：US20240016798A1

公开(公告)日：2024-01-18

申请号：US18370069

申请日：2023-09-19

Applicant: Serina Therapeutics, Inc.

Inventor： Michael Bentley ,  Zhihao Fang ,  Rebecca Weimer ,  Tacey Viegas ,  Randall Moreadith

IPC: A61K31/485 ,  A61K47/59 ,  A61K9/00 ,  A61K31/05 ,  A61K31/12 ,  A61K31/137 ,  A61K31/15 ,  A61K31/198 ,  A61K31/24 ,  A61K31/277 ,  A61K31/36 ,  A61K31/55 ,  A61K47/14 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22

CPC classification number: A61K31/485 ,  A61K47/595 ,  A61K9/0019 ,  A61K31/05 ,  A61K31/12 ,  A61K31/137 ,  A61K31/15 ,  A61K31/198 ,  A61K31/24 ,  A61K31/277 ,  A61K31/36 ,  A61K31/55 ,  A61K47/14 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/59

Abstract: Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.

公开(公告)号：US11858884B2

公开(公告)日：2024-01-02

申请号：US17566666

申请日：2021-12-30

Applicant: The Board of Regents of The University of Texas System

Inventor： Daniel J. Siegwart ,  Kejin Zhou

IPC: C07C321/14 ,  A61K9/51 ,  A61K31/7105 ,  A61K31/7125 ,  A61K47/59 ,  A61K47/60 ,  A61K47/69 ,  A61K48/00 ,  C07C323/52 ,  C07D295/15 ,  A61K47/20 ,  A61K47/22

CPC classification number: C07C321/14 ,  A61K9/513 ,  A61K9/5146 ,  A61K31/7105 ,  A61K31/7125 ,  A61K47/20 ,  A61K47/22 ,  A61K47/59 ,  A61K47/60 ,  A61K47/6931 ,  A61K48/0041 ,  C07C323/52 ,  C07D295/15

Abstract: Disclosed herein are methods for modulating an amount or activity of a gene or a gene product in a cell. The methods herein may comprise contacting a cell with a therapeutic agent assembled with a lipid composition, which lipid composition may comprise a dendrimer or dendron which may comprise one or more degradable diacyl group, in which may result in modulating the amount or activity of the gene or the gene product in the cell. The therapeutic agent modulating a gene or gene product in a cell may be sufficient to treat a disease or disorder in a subject. Further disclosed herein are pharmaceutical compositions, kits, and lipid compositions for modulating an amount or activity of a gene or a gene product in a cell.